Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELCADE Re-Treatment in Multiple Myeloma
NCT00257114Phase 4Completed
- Sponsor
- Millennium Pharmaceuticals
- Primary completion
- Mar 2007
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by Millennium Pharmaceuticals. Primary endpoint: Overall Response Rate. Status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00257114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00257114.